English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/134615
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine

AuthorsBonilla, Ximena; Dakir, El Habib; Mollinedo, Faustino ; Gajate, Consuelo
KeywordsEther phospholipid
Edelfosine
Xenograft animal model
Apoptosis
Endoplasmic reticulum
Ewing’s sarcoma
Issue Date2015
PublisherImpact Journals
CitationOncotarget 6(16): 14596-14613 (2015)
AbstractEwing’s sarcoma (ES) is the second most common bone cancer in children and young people. Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) is the prototype of a family of synthetic antitumor compounds, collectively known as alkylphospholipid analogs (APLs). We have found that APLs ranked edelfosine>perifosine>erucylphosphocholine>miltefosine for their capacity to promote apoptosis in ES cells. Edelfosine accumulated in the endoplasmic reticulum (ER) and triggered an ER stress response that eventually led to caspase-dependent apoptosis in ES cells. This apoptotic response involved mitochondrial-mediated processes, with cytochrome c release, caspase-9 activation and generation of reactive oxygen species. Edelfosine-induced apoptosis was also dependent on sustained c-Jun NH2-terminal kinase activation. Oral administration of edelfosine showed a potent in vivo antitumor activity in an ES xenograft animal model. Histochemical staining gave evidence for ER stress response and apoptosis in the ES tumors isolated from edelfosine-treated mice. Edelfosine showed a preferential action on ES tumor cells as compared to non-transformed osteoblasts, and appeared to be well suited for combination therapy regimens. These results demonstrate in vitro and in vivo antitumor activity of edelfosine against ES cells that is mediated by caspase activation and ER stress, and provide the proof of concept for a putative edelfosine- and ER stress-mediated approach forES treatment.
DescriptionThis is an open-access article distributed under the terms of the Creative Commons Attribution License.
Publisher version (URL)http://dx.doi.org/10.18632/oncotarget.4053
URIhttp://hdl.handle.net/10261/134615
DOI10.18632/oncotarget.4053
Identifiersdoi: 10.18632/oncotarget.4053
e-issn: 1949-2553
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
alkylphospholipid.pdf6,86 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.